Hein Heidbuchel

Learn More
Authors/Task Force Members: A. John Camm (Chairperson) (UK)*, Paulus Kirchhof (Germany), Gregory Y.H. Lip (UK), Ulrich Schotten (The Netherlands), Irene Savelieva (UK), Sabine Ernst (UK), Isabelle C. Van Gelder (The Netherlands), Nawwar Al-Attar (France), Gerhard Hindricks (Germany), Bernard Prendergast (UK), Hein Heidbuchel (Belgium), Ottavio Alfieri(More)
The current manuscript is an update of the original Practical Guide, published in June 2013[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51; Heidbuchel H, Verhamme P, Alings(More)
New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and patients will have to learn how to use these drugs effectively and safely in clinical practice. Many unresolved questions on how to optimally use these drugs in specific clinical(More)
Cardiovascular remodelling in the conditioned athlete is frequently associated with physiological ECG changes. Abnormalities, however, may be detected which represent expression of an underlying heart disease that puts the athlete at risk of arrhythmic cardiac arrest during sports. It is mandatory that ECG changes resulting from intensive physical training(More)
The 1996 American Heart Association consensus panel recommendations stated that pre-participation cardiovascular screening for young competitive athletes is justifiable and compelling on ethical, legal, and medical grounds. The present article represents the consensus statement of the Study Group on Sports Cardiology of the Working Group on Cardiac(More)
National Institute of Sports Medicine, Italian National Olympic Committee, Via dei Campi Sportivi 46, 00197 Rome, Italy; Cardiovascular Rehabilitation Unit, KU Leuven, Leuven, Belgium; Department of Heart Disease, Haukeland University Hospital, Bergen, Norway; Division of Inherited Cardiovascular Diseases, University of Athens, Athens, Greece; Department of(More)
BACKGROUND Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required. METHODS AND RESULTS The current analysis was undertaken to compare the periprocedural bleeding risk of patients in the Randomized Evaluation of(More)
OBJECTIVES Our purpose was to evaluate the efficacy of antiarrhythmic drugs (AADs) in recurrent ventricular fibrillation (VF) associated with inferolateral early repolarization pattern on the electrocardiogram. BACKGROUND Although an implantable cardioverter-defibrillator is the treatment of choice, additional AADs may be necessary to prevent frequent(More)
New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and patients will have to learn how to use these drugs effectively and safely in specific clinical situations. This text is an executive summary of a practical guide that the European(More)
Advisors: Azhar Ahmad, M.D. (Boehringer-Ingelheim Pharma), Jutta Heinrich-Nols, M.D. (Boehringer-Ingelheim Pharma), Susanne Hess, M.D. (Bayer Healthcare Pharmaceuticals), Markus Müller, M.D., Ph.D. (Pfizer Pharma), Felix Münzel, Ph.D. (Daiichi-Sankyo Europe), Markus Schwertfeger, M.D. (Daiichi-Sankyo Europe), Martin van Eickels, M.D. (Bayer Healthcare(More)